Triplixam 5mg/1.25mg/5mg 30 tablets — Made in Ireland — Free Delivery

Pharmachologic effect

Triplixam is a combined preparation that includes three antihypertensive components, each of which complements the action of the others to control blood pressure in patients with arterial hypertension. Amlodipine is a slow calcium channel blocker (BMCC), a dihydropyridine derivative, indapamide is a sulfonamide diuretic, perindopril arginine is an inhibitor of the enzyme that converts angiotensin I to angiotensin II (ACE inhibitor).

The pharmacological properties of the preparation Triplixam combine the properties of each of its active ingredients. In addition, the combination of amlodipine, indapamide and perindopril arginine enhances the antihypertensive effect of each of the components.

Indication for use

Therapy of arterial hypertension with a decrease in blood pressure while taking amlodipine, indapamide and perindopril in the same doses

Methods of administration and dosage

The preparation is taken orally, 1 tab. 1 time / day, preferably in the morning before meals.

The dose of the preparation Triplixam is selected after previously titrated doses of individual components.

The maximum daily dose is 1 tab. at a dosage of 10 mg + 2.5 mg + 10 mg.

Contraindications

• angioedema (Quincke's edema) while taking ACE inhibitors in history
• hereditary / idiopathic angioedema;
• severe renal failure (CC less than 30 ml / min);
• moderate renal failure (CC less than 60 ml / min) for the dosage of the combination of perindopril / indapamide 10 mg / 2.5 mg (i.e. Triplixam® 5 mg + 2.5 mg + 10 mg and Triplixam® 10 mg + 2.5 mg + 10 mg) ;
• patients on hemodialysis;
• bilateral stenosis of the renal arteries, stenosis of the artery of a single kidney;
• severe liver failure;
• hepatic encephalopathy;
• hypokalemia;
• severe arterial hypotension (systolic blood pressure less than 90 mm Hg);
• shock (including cardiogenic);
• untreated heart failure in the stage of decompensation;
• hemodynamically unstable heart failure after acute myocardial infarction;
• obstruction of the left ventricular outflow tract (eg, clinically significant aortic stenosis);
• simultaneous use with aliskiren-containing preparations in patients with diabetes mellitus or impaired renal function (GFR <60 ml / min / 1.73 m2 of body surface area)
• simultaneous use with preparations that can cause polymorphic ventricular tachycardia of the "pirouette" type;
• simultaneous use with preparations  that prolong the QT interval;
• simultaneous use with potassium-sparing diuretics, potassium and lithium preparations, in patients with an increased content of potassium in the blood plasma;
• pregnancy
• breastfeeding period
• age up to 18 years (efficacy and safety have not been established);
• hypersensitivity to the active and auxiliary substances that make up the preparation, sulfonamide derivatives, dihydropyridine derivatives, other ACE inhibitors, any other substances that make up the preparation.

Storage conditions

The preparation should be stored out of the reach of children at a temperature not exceeding 25 ° C.